PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
3.56%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-26.91%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-26.91%
Both companies reducing total costs. Martin Whitman would check industry trends.
10.26%
Interest expense change of 10.26% while AVXL maintains costs. Bruce Berkowitz would investigate control.
-96.48%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-115.63%
EBITDA decline while AVXL shows 100.03% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth below 50% of AVXL's 69.57%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Other expenses reduction while AVXL shows 155.09% growth. Joel Greenblatt would examine advantage.
-304.05%
Pre-tax income decline while AVXL shows 76.61% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense growth above 1.5x AVXL's 61.94%. Michael Burry would check for concerning trends.
-304.05%
Net income decline while AVXL shows 76.61% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
EPS decline while AVXL shows 76.67% growth. Joel Greenblatt would examine position.
-288.66%
Diluted EPS decline while AVXL shows 76.67% growth. Joel Greenblatt would examine position.
0.11%
Share count change of 0.11% while AVXL is stable. Bruce Berkowitz would verify approach.
3.68%
Diluted share change of 3.68% while AVXL is stable. Bruce Berkowitz would verify approach.